Local and Regional Control in Breast Cancer: Role of Sentinel Node Biopsy

Advances in Surgery

Volumn 45, Issue 1, 2011, Pages 101-116

  Giuliano, Armando E ^a   Han, Soo Hwa ^a  

^a SAINT JOHN'S HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST TUMOR; CANCER STAGING; FEMALE; HUMAN; LYMPH NODE; METHODOLOGY; PATHOLOGY; REVIEW; SEGMENTAL MASTECTOMY; SENTINEL LYMPH NODE BIOPSY; TUMOR RECURRENCE;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY;

EID: 79961196749     PISSN: 00653411     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yasu.2011.03.015     Document Type: Review

References (63)

1. American Cancer Society Cancer facts and figures 2010 2010, American Cancer Society, Atlanta (GA), p. 8-9.
2. Morton D.L., Wen D.R., Wong J.H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127:392-399.
3. Giuliano A.E., Kirgan D.M., Guenther J.M., et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994, 220:391-401.
4. Lyman G., Giuliano A.E., Somerfield M., et al. American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005, 23:7703-7720.
5. Buchholz T.A., Lehman C.D., Harris J.R., et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute Conference. J Clin Oncol 2008, 28:791-797.
6. Krag D.N., Weaver D.L., Alex J.C., et al. Surgical resection and radiolocalization of the sentinel lymph node breast cancer using a gamma probe. Surg Oncol 1993, 2:335-339.
7. Veronesi U., Paganelli G., Galimberti V., et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997, 349:1864-1867.
8. Borgstein P.J., Pijpers R., Comans E.F., et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998, 186:275-283.
9. Hill A.D., Tran K.N., Akhurst T., et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg 1999, 229:528-535.
10. Van der Ent F., Kengen R., van der Pol H., et al. Sentinel node biopsy in 70 unselected patients with breast cancer: increased feasibility by using 10mCi radiocolloid in combination with a blue dye tracer. Eur J Surg Oncol 1999, 25:24-29.
11. Grube B.J., Giuliano A.E. Sentinel lymph node dissection. Disease of the breast 2010, 547. Lippincott Williams & Wilkins, Philadelphia. 4th edition. J.R. Harris, M.E. Lippman, M. Morrow (Eds.).
12. De Cicco C., Cremonesi M., Luini A., et al. Lymphoscintigraphy and radio-guided biopsy of the sentinel axillary node in breast cancer. J Nucl Med 1998, 39:2080-2084.
13. Haigh P., Hansen N., Giuliano A., et al. Factors affecting sentinel node localization during preoperative breast lymphoscintigraphy. J Nucl Med 2000, 41:1682-1688.
14. McMasters K., Wong S., Tuttle T., et al. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes. Ann Surg 2000, 231:724-731.
15. Morrow M., Foster R.S. Staging of breast cancer, a new rationale for internal mammary node biopsy. Arch Surg 1981, 116:748-751.
16. Suami H., Pan W.R., Mann G.B., et al. The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study. Ann Surg Oncol 2008, 15:863-871.
17. Ciesl L., Mann G.B. Alternative sites of injection for sentinel lymph node biopsy in breast cancer. ANZ J Surg 2003, 73:600-604.
18. Alweis T.M., Badriyyah M., Ad V.B., et al. Current controversies in sentinel lymph node biopsy for breast cancer. Breast 2003, 12:163-171.
19. Noguchi M. Current controversies concerning sentinel lymph node biopsy for breast cancer. Breast Cancer Res Treat 2004, 84:261-271.
20. Borgstein P.J., Meijer S., Pijpers R. Intradermal blue dye to identify sentinel lymph nodes in breast cancer. Lancet 1997, 349:1668-1669.
21. Linehan D.C., Hill A.D., Akhurst T., et al. Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol 1999, 6:450-454.
22. Kimberg V.S., Rubio I.T., Henry R., et al. Subareolar versus peritumoral injection for location of the sentinel node. Am Surg 1999, 6:860-865.
23. Kern J.A. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye. J Am Coll Surg 1999, 189:539-545.
24. Povoski S.P., Olsen J.O., Young D.C., et al. Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol 2006, 13:1412-1421.
25. Rodier J.F., Velten M., Martel P., et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRASENODE trial. J Clin Oncol 2007, 24:3664-3669.
26. McMasters K., Wong S., Martin R.C., et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of the multi-institutional study. Ann Surg 2001, 233:767-787.
27. Martin R., Derossis A., Fey J., et al. Intradermal isotope injection is superior to intramammary in sentinel sentinel node biopsy for breast cancer. Surgery 2001, 130:432-438.
28. Schrenk P., Wayand W. Sentinel-node biopsy in axillary lymph-node staging for patients with multicentric breast cancer. Lancet 2001, 357:122.
29. Posther K., McCall L.M., Blumencranz P.W., et al. Sentinel node skills verification and surgeon performance data from a multicenter clinical trial for early-stage breast cancer. Ann Surg 2005, 242:593-602.
30. Morrow M., Rademaker A.W., Bethke K.P., et al. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery 1999, 126:714-720.
31. Meyer-Rochow G.Y., Martin R.C., Harman C.R. Sentinel node biopsy in breast cancer: validation study and comparison of blue dye alone with triple modality localization. ANZ J Surg 2003, 73:815-818.
32. Simmons R. Review of sentinel lymph node credentialing: how many cases are enough?. J Am Coll Surg 2001, 193:206-209.
33. The American Society of Breast Surgeons. Consensus statement on guidelines for performance of sentinel lymphadenectomy for breast cancer. 2000. Available at: http://www.breastsurgeons.org/statements/PDF_Statements/SLN_Dissection.pdf.
34. The American Society of Breast Surgeons. Consensus statement on guidelines for performance of sentinel lymphadenectomy for breast cancer. 2005. Available at: http://www.breastsurgeons.org/statements/PDF_Statements/SLN_Dissection.pdf.
35. Krag D.N., Anderson S.J., Julian T.B., et al. Technical outcomes of sentinel-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomized phase III trial. Lancet Oncol 2007, 8:881-888.
36. Zakaria S., Degnim A.C., Kleer C.G., et al. Sentinel lymph node biopsy for breast: how many nodes are enough?. J Surg Oncol 2007, 96:554-559.
37. Chagpar A.B., Scoggins C.R., Martin R.C., et al. Are 3 sentinel nodes sufficient?. Arch Surg 2007, 142:456-460.
38. Goyal A., Newcombe R., Chhabra A., et al. Factors affecting failed localization and false-negative rates of sentinel node biopsy in breast cancer - results of the ALMANAC validation phase. Breast Cancer Res Treat 2006, 99:203-208.
39. Krag D.N., Anderson S.J., Julian T.B., et al. Sentinel-lymph-node resection compared with axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010, 11(10):927-933.
40. Ashikaga T., Krag D.N., Land S.R., et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010, 102(2):111-118.
41. Gill P.G. Sentinel lymph node biopsy versus axillary clearance in operable breast cancer. The RACS SNAC trial. A multicenter randomized trial of the Royal Australian College of Surgeons (RACS) section of breast surgery in collaboration with the National Health and Medical Research Council Clinical Trials Center. Ann Surg Oncol 2004, 11:216S-221S.
42. Gill G. SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 2009, 16(2):266-275.
43. Zavagno G., De Salvo G.L., Scalco G., et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer. Results of the Sentinella/GIVOM trial. Ann Surg 2008, 247:207-213.
44. Weaver D.L. Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale. Mod Pathol 2010, 23(Suppl 2):S26-S32.
45. AJCC cancer staging manual 2010, 347-376. Springer, New York. 7th edition. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.).
46. Giuliano A.E., Haigh P.I., Brennan M.B., et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000, 18:2553-2559.
47. Zavagno G., Carcoforo P., Franchini Z., et al. Axillary recurrence after negative sentinel lymph node biopsy without axillary dissection: a study of 479 breast cancer patients. Eur J Surg Oncol 2005, 31:715-720.
48. Bergkvist L., de Boniface J., Jonsson P.-E., et al. Axillary recurrence rate after negative sentinel node biopsy in breast cancer. Three-year follow-up of the Swedish multicenter cohort study. Ann Surg 2008, 247(1):150-156.
49. Naik A.M., Fey I.V., Gemagnani M., et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up of 4,008 procedures. Ann Surg 2004, 240:462-471.
50. Veronesi U., Viale G., Paganelli G., et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010, 251(4):595-600.
51. Van der Ploeg I.M., Niewig O.E., Van Rijk M.C., et al. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol 2008, 34(12):1277-1284.
52. Fisher B., Jeong J.H., Anderson S., et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002, 347(8):567-575.
53. Hansen N.M., Grube B.J., Giuliano A.E. The time has come to change the algorithm for the surgical management of early breast cancer. Arch Surg 2002, 137(10):1131-1135.
54. Park J., Fey J.V., Naik A.M., et al. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg 2007, 245:462-468.
55. Fant J.S., Grant M.D., Knox S.M., et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol 2003, 10:126-130.
56. Guenther J.M., Hansen N.M., DiFronzo L.A., et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg 2003, 138:52-56.
57. Winchester D.J., Sener S.F., Brinkman E.M., et al. Axillary recurrence following sentinel node biopsy. Ann Surg Oncol 2005, 11:S58.
58. Fisher B., Montague E., Redmond C., et al. Comparison of radical mastectomy with alternative treatments for primary nreast cancer. A first report of results from a prospective randomized clinical trial. Cancer 1977, 39(Suppl 6):2827-2839.
59. Martelli G., Boracchi P., De Palo M., et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg 2005, 242(1):1-6. [discussion: 7-9].
60. International Breast Cancer Study Group Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of international breast cancer study group trial 10-93. J Clin Oncol 2006, 24(3):337-344.
61. Hurkmans C.W., Beorger J.H., Rutgers E.J., et al. Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run. Radiother Oncol 2003, 68:233-240.
62. Giuliano A.E., McCall L., Beitsch P., et al. Locoregional recurrence after sentinel lymph node dissection with and without axillary dissection in patients with sentinel lymph node metastases. The American College of Surgeons Oncology Group Z0011 Randomized Trial. Ann Surg 2010, 252(3):426-432.
63. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005, 366:2087-2106.